172 related articles for article (PubMed ID: 30226476)
1. Vismodegib treatment in a HIV positive patient on antiretroviral therapy.
Scalvenzi M; Villani A; Mazzella C; Cappello M; Salvatores GF; Costa C
Indian J Dermatol Venereol Leprol; 2018; 84(6):758-760. PubMed ID: 30226476
[No Abstract] [Full Text] [Related]
2. A Novel Alternate Dosing of Vismodegib for Treatment of Patients With Advanced Basal Cell Carcinomas.
Becker LR; Aakhus AE; Reich HC; Lee PK
JAMA Dermatol; 2017 Apr; 153(4):321-322. PubMed ID: 28114606
[No Abstract] [Full Text] [Related]
3. Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation.
Chanu P; Musib L; Wang X; Cheeti S; Girish S; Bruno R; Lu T; Reddy J; Jin JY; Caro I
J Invest Dermatol; 2021 Apr; 141(4):930-933. PubMed ID: 32976880
[No Abstract] [Full Text] [Related]
4. PRISModegib: the use of the PRISM test to assess the health-related quality of life of patients with locally advanced basal cell carcinoma undergoing Hedgehog pathway inhibitor therapy.
Gualdi G; Moro R; Regina V; Caravello S; Monari P; Calzavara-Pinton PG
Br J Dermatol; 2019 Aug; 181(2):406-407. PubMed ID: 30737996
[No Abstract] [Full Text] [Related]
5. BCC and vismodegib: can we treat and remold at the same time?
Russo F; Mancini V; Trovato E; Fimiani M; Taddeucci P
G Ital Dermatol Venereol; 2020 Feb; 155(1):119-120. PubMed ID: 29781264
[No Abstract] [Full Text] [Related]
6. Outcomes for Basal Cell Carcinoma Treated With Vismodegib Extended Alternate Day Dosing.
Routt E; Ratner D
Dermatol Surg; 2020 Aug; 46(8):1109-1112. PubMed ID: 31274526
[No Abstract] [Full Text] [Related]
7. Vismodegib for the treatment of aggressive basal cell carcinoma in a patient unable to swallow pills.
Umanoff N; Sarbib K; Mulvaney M; Iorizzo L
Dermatol Surg; 2015 Mar; 41(3):433-5. PubMed ID: 25738448
[No Abstract] [Full Text] [Related]
8. Effective and Tolerable Treatment of Advanced Basal Cell Carcinoma With Vismodegib Despite Renal Insufficiency.
Maul LV; Kähler KC; Hauschild A
JAMA Dermatol; 2016 Dec; 152(12):1387-1388. PubMed ID: 26720040
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of vismodegib in patients with basal cell carcinoma: An Italian Center experience.
Scalvenzi M; Villani A; Costa C; Cappello M
Dermatol Ther; 2019 Jul; 32(4):e12971. PubMed ID: 31124200
[No Abstract] [Full Text] [Related]
10. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
Pollom EL; Bui TT; Chang AL; Colevas AD; Hara WY
JAMA Dermatol; 2015 Sep; 151(9):998-1001. PubMed ID: 25874733
[TBL] [Abstract][Full Text] [Related]
11. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single centre experience.
Woltsche N; Pichler N; Wolf I; Di Meo N; Zalaudek I
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e144-e145. PubMed ID: 30472793
[No Abstract] [Full Text] [Related]
12. Hepatotoxicity Associated With Vismodegib: Could Dose Reduction Be an Effective Management?
de Perosanz-Lobo D; Burgos-Blasco P; Moreno-Arrones OM; Bea-Ardebol S
Dermatol Surg; 2021 Jul; 47(7):1006-1007. PubMed ID: 34167133
[No Abstract] [Full Text] [Related]
13. [Vismodegib Therapy for Periocular Basal Cell Carcinoma].
Keserü M; Green S; Dulz S
Klin Monbl Augenheilkd; 2017 Jan; 234(1):64-69. PubMed ID: 28135752
[No Abstract] [Full Text] [Related]
14. Comparison of daily dosing versus Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: A retrospective case series.
Wong C; Poblete-Lopez C; Vidimos A
J Am Acad Dermatol; 2020 Jun; 82(6):1539-1542. PubMed ID: 32092372
[No Abstract] [Full Text] [Related]
15. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
[TBL] [Abstract][Full Text] [Related]
16. Histopathology of Basal Cell Carcinoma After Treatment With Vismogedib.
Tang JC; Buckel L; Hanke CW
J Drugs Dermatol; 2019 Feb; 18(2):136-138. PubMed ID: 30794363
[TBL] [Abstract][Full Text] [Related]
17. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma.
Alcalay J; Tauber G; Fenig E; Hodak E
J Drugs Dermatol; 2015 Mar; 14(3):219-23. PubMed ID: 25738842
[TBL] [Abstract][Full Text] [Related]
18. Systemic therapy for advanced basal cell carcinoma.
Maybury CM; Craythorne EE; Urbano TG; Mallipeddi R
Lancet Oncol; 2015 Jun; 16(6):608-10. PubMed ID: 25981816
[No Abstract] [Full Text] [Related]
19. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: pseudocysts as a sign of tumor regression.
Maier T; Kulichova D; Ruzicka T; Berking C
J Am Acad Dermatol; 2014 Oct; 71(4):725-30. PubMed ID: 24928708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
